An evaluation of long-term survival from time of diagnosis in pulmonary arterial hypertension from the REVEAL Registry.
about
Calcium channel blockers for pulmonary arterial hypertensionTreatment satisfaction is associated with improved quality of life in patients treated with inhaled treprostinil for pulmonary arterial hypertensionThe Role of Hyperglycemia and Insulin Resistance in the Development and Progression of Pulmonary Arterial HypertensionSafety, efficacy, and clinical utility of macitentan in the treatment of pulmonary arterial hypertensionSurgical and transcatheter management alternatives in refractory pulmonary hypertension: Potts shuntThe molecular targets of approved treatments for pulmonary arterial hypertensionEpigenetic modulation as a therapeutic approach for pulmonary arterial hypertensionManagement of pulmonary vasodilator therapy in patients with pulmonary arterial hypertension during critical illnessOptimal management of pulmonary arterial hypertension: prognostic indicators to determine treatment courseAdaptation and validation of the Cambridge Pulmonary Hypertension Outcome Review (CAMPHOR) for the Netherlands.Perioperative Evaluation of Patients with Pulmonary Conditions Undergoing Non-Cardiothoracic SurgeryTreatment-related biomarkers in pulmonary hypertensionPulmonary arterial hypertension associated with congenital heart disease and Eisenmenger syndrome: current practice in pediatricsTreprostinil for the treatment of pulmonary arterial hypertensionTemperature variations around medication cassette and carry bag in routine use of epoprostenol administration in healthy volunteersPulmonary Arterial Hypertension and the Sex Hormone Paradox.Systematic Review of Health-Related Quality of Life in Patients with Pulmonary Arterial Hypertension.Living with pulmonary hypertension: unique insights from an international ethnographic study.MicroRNA-140-5p and SMURF1 regulate pulmonary arterial hypertension.Pulmonary hypertension: a guide for GPs.Safety of regadenoson stress testing in patients with pulmonary hypertension.Pulmonary hypertension in wild type mice and animals with genetic deficit in KCa2.3 and KCa3.1 channels.Targeted drugs for pulmonary arterial hypertension: a network meta-analysis of 32 randomized clinical trials.Prognostic value of echocardiographic changes in patients with pulmonary arterial hypertension receiving parenteral prostacyclin therapy.The Modified Borg Dyspnea Scale does not predict hospitalization in pulmonary arterial hypertension.Identifying "super responders" in pulmonary arterial hypertension.Open label study of ambrisentan in patients with exercise pulmonary hypertension.Shorter survival in familial versus idiopathic pulmonary arterial hypertension is associated with hemodynamic markers of impaired right ventricular functionFrom short-term benefits to long-term outcomes: the evolution of clinical trials in pulmonary arterial hypertensionSafety of cardiac catheterization at a center specializing in the care of patients with pulmonary arterial hypertensionPulmonary arterial hypertension in adults: novel drugs and catheter ablation techniques show promise? Systematic review on pharmacotherapy and interventional strategies.Switching from sildenafil to riociguat for the treatment of PAH and inoperable CTEPH: Real-life experiences.Endothelial cell global positioning system for pulmonary arterial hypertension: homing in on vascular repair.Inhibition of phosphodiesterase 2 augments cGMP and cAMP signaling to ameliorate pulmonary hypertension.Quality of life as a prognostic marker in pulmonary arterial hypertensionPharmacologic treatments for pulmonary hypertension: exploring pharmacogenomicsRiociguat (adempas): a novel agent for the treatment of pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension.Life span of patients with Eisenmenger syndrome is not superior to that of patients with other causes of pulmonary hypertension.Macitentan for the treatment of pulmonary arterial hypertension.Mineralocorticoid receptors in vascular disease: connecting molecular pathways to clinical implications.
P2860
Q24187010-B2B4CBA0-3E98-4C62-82C8-52CBE6620E89Q24598400-785E28C1-7C63-4328-8538-6B31598BC0DBQ26744761-B401ACBA-9664-4A7C-8B90-9380D8633C85Q26747812-96859C2A-EC7F-4131-A6AB-790E2683277BQ26782099-D935879E-DAF0-4116-BFC0-2FF51980FF83Q26798308-B11F4689-AA59-42D5-9D15-7FA1D9031F4BQ26801345-9EB14A02-92FF-4D97-8082-DC8C2EFE4F7EQ26863639-AC094A5B-4858-488A-8F7E-A9EC2D97BC55Q27023074-8594D4B7-AAF3-496F-BA37-2A68D0CEF91FQ27342609-E88D780D-94A8-43D7-93F3-9E2146F797E0Q28072690-EDBC8C7F-ED79-4FDE-8B96-67F6853AA7FBQ28081276-3EB07F19-3148-482E-B33D-DA048C4466BEQ28085572-4DD07DAB-A2ED-4CD1-B68C-C4B1D9D16CDEQ28281899-68A9762A-8D62-4250-AFD6-882DE89B6952Q28484599-5F0395B1-ACD2-4754-AF4F-FA2FDF9D9BB7Q30241478-7134ACEA-2E5E-453F-AA55-D8A1B489C70AQ30251818-84C904D4-6AF5-404C-BCFF-1C728AB4CAF8Q30578342-3EE6125F-5B67-438A-9AB1-0D19EAED2C9BQ32884516-AD1C5F72-3F5A-45FE-AB40-AF6388237E4AQ33162106-FF8CBB27-2A9F-499C-BCD0-A2F0155EB0D5Q33167948-FC8D0862-CDA9-429A-AC1C-2B07860E4C2EQ33654786-08B86929-CB30-4897-A996-D0B8A566B748Q33673947-AE25D8E6-E544-4C41-B045-0A87397FFED5Q33787275-F21FD5E9-7121-44CC-935E-1132956313EEQ33788447-0AA33BA4-9ADB-447C-8E99-9445D053F8B8Q33788452-7B067AB1-81ED-4B68-9C69-15ECC9F46BC2Q33788564-64D5AF8A-6F56-4502-B9F0-EEFAA55F523CQ33806077-E87C6302-C441-402B-A91D-C8309DB136FDQ33806102-F3E21E64-9FE6-46AA-8B53-AA11F5008D81Q33806197-5DAEDD52-B26B-4C49-965A-3F4C6E1353D9Q33810499-834E0D9F-C2A3-4C95-B6FD-668FA5CBB981Q33812297-A22316EF-2A57-475F-8EF9-4DCBB41E07A6Q33839496-F3830C57-7555-41F9-9364-FF84BFE59CA1Q34011572-FF37555B-FC39-4413-910A-0E74594C78F7Q34207690-0A903B15-78A0-44B6-AF0B-DD3E521CB7EBQ34344390-9700C965-A519-4AA6-8688-D6C76BEEEA0AQ34444990-F833764E-31DF-4422-93C3-DAB39EF66CF3Q34457779-B6374543-DCA4-4D06-8460-6EC6C4479356Q34610092-9D5D9B23-AF20-420D-964B-BCB5713374A4Q34684861-070C04E1-1694-465B-9700-71FD514EBDB6
P2860
An evaluation of long-term survival from time of diagnosis in pulmonary arterial hypertension from the REVEAL Registry.
description
2012 nî lūn-bûn
@nan
2012 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
2012 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
name
An evaluation of long-term sur ...... sion from the REVEAL Registry.
@ast
An evaluation of long-term sur ...... sion from the REVEAL Registry.
@en
An evaluation of long-term sur ...... sion from the REVEAL Registry.
@nl
type
label
An evaluation of long-term sur ...... sion from the REVEAL Registry.
@ast
An evaluation of long-term sur ...... sion from the REVEAL Registry.
@en
An evaluation of long-term sur ...... sion from the REVEAL Registry.
@nl
prefLabel
An evaluation of long-term sur ...... sion from the REVEAL Registry.
@ast
An evaluation of long-term sur ...... sion from the REVEAL Registry.
@en
An evaluation of long-term sur ...... sion from the REVEAL Registry.
@nl
P2093
P356
P1433
P1476
An evaluation of long-term sur ...... sion from the REVEAL Registry.
@en
P2093
Adaani E Frost
Dave P Miller
David B Badesch
Michael D McGoon
Raymond L Benza
Robyn J Barst
P304
P356
10.1378/CHEST.11-1460
P407
P577
2012-08-01T00:00:00Z